Navigation Links
St. Louis Park Vapor Systems Installation Nearly Complete; Meeting July 10
Date:6/17/2008

CHICAGO, June 17 /PRNewswire-USNewswire/ -- U.S. Environmental Protection Agency Region 5 this week nears completion of a $1 million effort to contain potential hazards from underground soil contamination in St. Louis Park, Minn.

A pair of open house-style meetings to update area residents and businesses are scheduled for July 10, 2 to 4 p.m. and 6 to 8 p.m., at the St. Louis Park Senior High School cafeteria, 6425 W. 33rd St. EPA's storefront office at 6528 W. Lake St., Ste. F., will close on June 30, though the 952-922-2035 phone number will be maintained for residents to leave messages.

EPA became involved in the St. Louis Park project in December 2007, prompted by the discovery of vapors from volatile organic compounds, or VOCs, in area ground water samples. The VOCs have no effect on local drinking water supplies, but vapors could rise through the soil into basements and foundation cracks.

Over the course of the project, EPA collected soil samples from 268 properties (219 residential, 49 commercial/industrial) in an area near the

intersection of Highway 7 and Wooddale Avenue. Of these, 41 residential

and 12 commercial/industrial properties had subslab and/or indoor air VOC levels that exceeded the Minnesota Department of Health's screening levels. The screening levels are protective of public health. They are used to determine if more investigation is needed to prevent long-term exposure to low levels of vapors.

EPA has installed vapor-abatement systems at no cost at 40 of the 41 properties that exceeded the MDH screening level. (One property owner did not provide installation access after the initial sampling.) The vapor-abatement systems resemble commonly seen radon gas-abatement systems.

Follow up subsurface and indoor air sampling of those residences with vapor-abatement systems will be conducted 30 days and 90 days after installation.

An investigation into possible sources of the contamination,
'/>"/>

SOURCE U.S. Environmental Protection Agency Region 5
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Louisiana May Mandate Fluoridation Despite Evidence of Harm
2. NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital
3. Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd
4. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
5. Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants
6. Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight
7. Washington University in St. Louis and AstraZeneca Announce Alzheimers Research Collaboration
8. Louisiana Advisor to Speak Nationwide
9. Revise guidelines for weight gain during pregnancy, says Saint Louis U. obstetrician
10. St. Louis University Hospital Purchases Second CyberKnife(R) System
11. Bright Options for Medicare Beneficiaries in Louisiana
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 1DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 2DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 3Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3